IC
RCKT icon

Ikarian Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Ikarian Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-221,911
Closed -$1.48M – 179
2025
Q1 		$1.48M Hold
221,911
– – 0.18% 82
2024
Q4 		$2.79M Buy
221,911
+24,815
+13% +$374K 0.38% 67
2024
Q3 		$3.64M Hold
197,096
– – 0.51% 57
2024
Q2 		$4.24M Sell
197,096
-100,000
-34% -$2.3M 0.74% 33
2024
Q1 		$8M Buy
297,096
+57,370
+24% +$1.63M 0.88% 37
2023
Q4 		$7.18M Sell
239,726
-415,000
-63% -$9.16M 0.67% 51
2023
Q3 		$13.4M Buy
+654,726
New +$11.9M 1.61% 15
2021
Q2 		– Sell
-1,400
Closed -$61K – 268
2021
Q1 		$61K Hold
1,400
– – ﹤0.01% 282
2020
Q4 		$75K Buy
+1,400
New +$51K ﹤0.01% 217

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Ikarian Capital's RCKT Position: Q2 2025 in Review

Ikarian Capital sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 221,911 shares — an estimated $1.48M sold.

Ikarian Capital first reported a position in RCKT in Q4 2020 and held it in 9 quarters. The position peaked at $13.4M in Q3 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Ikarian Capital reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 221,911 Rocket Pharmaceuticals shares in Q2 2025, an estimated $1.48M.
  • Ikarian Capital first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Ikarian Capital's Rocket Pharmaceuticals position peaked at $13.4M in Q3 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.